Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlpha Teknova Inc

Alpha Teknova Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
7.81 USD -0.07 ( 0.89%)
Last update at 2026-11-06T21:00:00Z
VOLUME
546270
Market Cap
370.45M

Momentum Score

…

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.69
Low
8.51
High
52 Week Price Range
1.91
Low
7.84
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alpha Teknova Inc manufactures and supplies high-performance reagents, custom buffers and contract manufacturing services for life-science research, diagnostics and biopharma customers. Long-term growth drivers include rising demand for molecular biology consumables and custom manufacturing, expansion of product lines and geographies, and recurring revenue from consumable sales, which may benefit revenue stability. Investors may find the company attractive for exposure to recurring consumables demand and scalable manufacturing capabilities.
Material risks include intense competition from large established suppliers, margin pressure and execution risk in scaling manufacturing, sensitivity to research funding and regulatory compliance; investors should monitor customer concentration and supply-chain resilience.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.88
Dividend Yield
-
Revenue TTM
43.70M
Revenue Per Share
0.82
Gross Profit TTM
15.12M
Debt / Equity
0.22
ROE
-24.19%
Net Debt
9.23M
ROCE
-17.17%
Diluted EPS TTM
-0.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -17.20M -26.83M -37.08M -49.39M -12.64M
Net income -17.26M -26.75M -36.78M -47.47M -9.80M
Selling general administrative 20.32M 23.15M 25.45M 28.30M 20.39M
Selling and marketing expenses 6.75M 6.32M 9.33M 9.15M 3.78M
Gross profit 13.44M 7.23M 10.30M 17.48M 17.62M
Reconciled depreciation 6.34M 6.58M 4.94M 3.17M 2.88M
Ebit -16.49M -26.15M -31.20M -28.86M -12.01M
Ebitda -10.15M -19.57M -25.54M -4.89M -9.12M
Depreciation and amortization 6.34M 6.58M 5.66M 23.97M 2.88M
Non operating income net other - - - - -0.04M
Operating income -16.98M -26.15M -35.56M -28.86M -12.01M
Other operating expenses 57.50M 63.89M 72.25M 70.28M 48.90M
Interest expense 0.71M 0.69M 0.83M 0.21M -0.59M
Tax provision 0.06M -0.09M -0.79M -1.92M -2.83M
Net interest income -0.71M -0.69M -0.88M 0.21M -0.59M
Income tax expense 0.06M -0.09M -0.30M -1.92M -2.83M
Total revenue 40.52M 37.74M 36.68M 41.42M 36.89M
Total operating expenses 30.42M 33.38M 45.86M 46.33M 29.63M
Cost of revenue 27.08M 30.51M 26.39M 23.94M 19.27M
Total other income expense net -0.23M -0.69M -1.51M -20.53M -0.63M
Net income from continuing ops -17.26M -26.75M -39.42M -47.47M -9.80M
Net income applicable to common shares - - - -47.47M -9.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 103.58M 118.77M 128.59M 152.26M 166.51M
Intangible assets 11.94M 13.09M 14.24M 17.56M 18.70M
Other current assets 16.93M 1.27M 1.63M 2.37M 2.44M
Total liab 34.81M 36.38M 38.55M 52.38M 23.31M
Total stockholder equity 68.78M 82.39M 90.04M 99.89M 143.20M
Deferred long term liab - - - - 3.42M
Other current liab 4.28M 4.51M 5.56M 6.00M 5.50M
Common stock 0.00M 0.00M - - -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -135.79M -118.53M -91.79M -55.01M -7.54M
Other liab - - - 1.41M 3.69M
Good will - - - 0.00M 16.61M
Other assets - - - - 0.18M
Cash 5.91M 3.71M 28.48M 42.24M 87.52M
Total current liabilities 7.54M 11.21M 8.88M 10.88M 7.74M
Current deferred revenue - 0.03M 0.02M 0.20M -
Net debt 9.23M 26.46M 1.97M 0.07M -75.65M
Short term debt 1.88M 5.84M 1.80M 2.22M -
Short long term debt - 4.04M - - -
Short long term debt total 15.15M 30.17M 30.46M 42.31M 11.87M
Other stockholder equity 204.56M 200.92M 181.82M 154.89M -15.77M
Property plant equipment - - - 71.31M 29.81M
Total current assets 34.51M 42.78M 45.66M 61.14M 101.20M
Net tangible assets - - - - 107.89M
Short term investments 15.43M 26.69M - - 0.00M
Net receivables 4.62M 4.31M 3.95M 4.28M 5.85M
Long term debt 13.12M 9.44M 13.25M 21.98M 11.87M
Inventory 7.05M 6.80M 11.59M 12.25M 5.39M
Accounts payable 1.38M 0.82M 1.49M 2.45M 2.25M
Retained earnings total equity - - - - -7.54M
Non currrent assets other 1.28M 1.38M 1.85M 2.25M 0.18M
Non current assets total 69.07M 75.99M 82.93M 91.12M 65.31M
Capital lease obligations 15.15M 16.68M 17.21M 20.33M -
Long term debt total - - - - 11.87M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 11.85M -27.27M -12.35M -28.15M 1.83M
Change to liabilities - - - 0.57M 0.27M
Total cashflows from investing activities 10.70M -27.27M -7.74M -28.15M -17.52M
Net borrowings 1.11M 0.00M -10.00M 10.13M 11.89M
Total cash from financing activities 0.15M 14.89M 12.80M 10.27M 110.79M
Change to operating activities - - - -1.90M 0.51M
Net income -17.26M -26.75M -36.78M -47.47M -9.80M
Change in cash 2.20M -24.78M -13.75M -45.28M 84.20M
Begin period cash flow 3.71M 28.48M 42.24M 87.52M 3.31M
End period cash flow 5.91M 3.71M 28.48M 42.24M 87.52M
Total cash from operating activities -8.65M -12.39M -18.81M -27.40M -9.07M
Issuance of capital stock 0.00M 15.10M 22.91M 0.00M 102.67M
Depreciation 6.34M 6.58M 5.66M 3.17M 2.88M
Other cashflows from investing activities - 0.12M 0.20M - 0.53M
Dividends paid - - 0.25M - -
Change to inventory -2.37M 0.24M 0.33M -7.55M -2.25M
Change to account receivables -0.37M -0.49M 0.31M 0.38M -0.28M
Sale purchase of stock 0.06M 0.14M 0.25M 0.29M 99.06M
Other cashflows from financing activities -1.17M -0.21M 0.30M 10.00M 8.12M
Change to netincome - - - 23.96M -0.76M
Capital expenditures 1.15M 1.12M 7.93M 28.15M 19.88M
Change receivables - - - - -0.28M
Cash flows other operating - - - - -1.25M
Cash and cash equivalents changes - - - - 84.20M
Change in working capital -2.68M -0.87M 2.25M -7.33M -1.70M
Stock based compensation 3.43M 3.67M 4.14M 3.71M 1.55M
Other non cash items 1.47M 5.08M 6.22M 22.46M 0.84M
Free cash flow -9.79M -13.52M -26.75M -55.55M -28.95M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TKNO
Alpha Teknova Inc		 -0.07
0.89%		 7.81 - - 8.48 5.83 8.58 -6.23
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Alpha Teknova Inc

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

2451 Bert Dr., Hollister, CA, United States, 95023

831 637 1100

https://www.teknova.com

158

Name Title Year Born
Mr. Stephen Gunstream Pres, CEO & Director 1980
Mr. Matthew C. Lowell Chief Financial Officer 1971
Mr. Ken Gelhaus Chief Commercial Officer 1983
Mr. Damon A. Terrill Gen. Counsel, Chief Compliance Officer & Sec. 1971
Ms. Jennifer Henry Sr. VP of Marketing NA
Ms. Lisa Hood McCann Chief People Officer 1982
Mr. Stephen Gunstream President, CEO & Director 1980
Mr. Damon A. Terrill General Counsel, Chief Compliance Officer & Secretary 1971
Ms. Jennifer Henry Senior Vice President of Marketing NA
Mr. Damon A. Terrill J.D. General Counsel, Chief Compliance Officer & Secretary 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…